Material Safety Data Sheet

Biogen, Inc.                              24-Hour Emergency Phone:
14 Cambridge Center                       1 (800) 262 4363
Cambridge, MA 02142                       Biogen Environmental Health & Safety:
(617) 679-2000                            1 (617) 679 2236


Section 1. Identification

Product Name: LFA-3 Immunoglobulin Fusion Protein Chemical Name: LFA-3 Immunoglobulin Fusion Protein CAS Number: None Substance: LFA-3 Immunoglobulin Fusion Protein (LFA3TIP) is a fusion protein that is obtained from cultured recombinant Chinese Hamster Ovary cells. Other Names or Code Numbers: LFA3TIP, BG9273, BG9712, LFA-3/IgG1 Fusion Protein

Section 2. Composition / Information on Ingredients

Components % Optional OSHA PEL ACGIH TLV OTHER STANDARDS LFA3TIP (bulk intermediate) 65 - 90% n/a n/a none known (final product) 65 - 90% n/a n/a none known LFA3TIP is obtained from cultured recombinant Chinese Hamster Ovary (CHO) cells in a nutrient medium of proteins, amino acids, vitamins, glucose, and salts in purified water. The bulk intermediate is contained in a frozen aqueous solution. This solution does not contain any hazardous components, as defined by the OSHA Hazard Communication Standard (29 CFR 1910.1200), at concentrations above 1%.

Section 3. Hazards Identification

General Statement: CAUTION: THE CHEMICAL, PHYSICAL, AND TOXICOLOGICAL PROPERTIES OF LFA3TIP HAVE NOT BEEN THOROUGHLY INVESTIGATED. EXERCISE CARE TO PREVENT CONTACT OR EXPOSURE. Carcinogen Status: OSHA: No NTP: No IARC: No Carcinogen Statement: Mutagenic Effects: None observed in animal studies. LFA3TIP is non-mutagenic and non-clastogenic. It was negative in the Salmonella typhimurium and Escherichia coli plate incorporation mutation assays, and in an in vitro human peripheral blood lymphocyte chromosome aberration assay. Teratogenic Effects: None observed in animal studies. Reproductive Effects: None observed in animal studies. See Section 11. Neurotoxic Effects: None observed in animal studies.

Section 4. First Aid Measures

If Inhaled: Remove to fresh air. Get medical attention. If breathing has stopped, give artificial respiration. Treat symptomatically and supportively If Swallowed: Wash out with water. In Case of Skin or Eye Contact: No data available. Flush at least 15 minutes with water. Wash exposed skin with soap and water. Contact physician if irritation persists. Skin Absorption: No data available. If Injected: No data available. Medical Conditions Aggravated by Exposure: No data available.

Section 5. Fire Fighting Measures

Flash Point: No data available oC Flammable Limits: n/a Extinguishing Media: Use water spray, CO2, ABC Dry Chemical, or Foam Special Fire Fighting Materials: No special procedures. Unusual Fire and Explosion Hazards: No data available.

Section 6. Accidental Release Measures

Spill/Leak Procedures: Wear gloves, safety glasses or goggles, and lab coat or coveralls to prevent contact. Wipe working surfaces to dryness, then wash with soap and water. Confine and contain small spills using inert material (e.g. paper towels, spill control pillows, absorbants). In the event of a large spill, dike the area to prevent runoff. Clean the spill area with soap and water. Discard spill clean up materials in accordance with local regulations. In addition, comply with local regulations concerning spill reporting.

Section 7. Handling and Storage

Handle all pharmaceutical products in a way that will avoid contact with and inhalation of dust, fumes, mists, and/or vapors associated with the product. No special safety procedures are required for storing this product.

Section 8. Exposure Control / Personal Protection

Keep container tightly closed. Wear gloves to prevent skin contact. Replace gloves which become torn or punctured. Wash hands with soap and water whenever gloves are removed. Either safety glasses with side shields, or goggles, should be worn when ha ndling this material to prevent eye contact. Lab coat, apron, or other impermeable clothing may be worn when handling LFA3TIP.

Section 9. Physical and Chemical Properties

Molecular Formula:glycoprotein Molecular Weight: 119 kilodaltons Appearance/Odor: Odorless solution and/or frozen solid Solubilities: Up to 50mg/mL in water; No data available for other solvents Boiling Point: < 100 °C (decomposes) Melting Point: Approximately 0 °C Vapor Pressure (mm HG): No data available Vapor Density (Air = 1): No data available Specific Gravity (H20 = 1): No data available pH: 7.5 +/- 0.3

Section 10. Stability and Reactivity

LFA-3 Immunoglobulin Fusion Protein is Stable Hazardous Polymerization: No data available Incompatible Materials: No data available Conditions to Avoid: No data available Hazard Decomposition Products: No data available

Section 11. Toxicology Information

CAUTION: THE CHEMICAL, PHYSICAL, AND TOXICOLOGICAL PROPERTIES OF LFA3TIP HAVE NOT BEEN THOROUGHLY INVESTIGATED. THERE ARE NO DATA ON EFFECTS FOLLOWING ACUTE INHALATION, INGESTION, SKIN OR EYE EXPOSURE. ANY TOXICOLOGICAL DATA ON THE CHRONIC EFFECTS OF THIS PRODUCT ARE PROVIDED BELOW. WORKERS SHOULD EXERCISE CAUTION AND USE WORK PRACTICES WHICH MINIMIZE ANY CONTACT OR EXPOSURE WHEN HANDLING THIS MATERIAL. Target Organ Effects Data (Subchronic/chronic): Single and repeat dose studies were conducted in baboons to determine the potential toxicity of LFA3TIP following intravenous administration of doses up to 20 mg/ kg. Baboons were clinically normal (unremarkable clinical observations) during the treatment and post-treatment periods. The pharmacological effects of LFA3TIP included a decrease in the absolute number of peripheral blood and lymphoid organ T-lymphocytes. Single intravenous doses ( greater than or equal to 1.0 mg/kg) administered approximately every 3 days for one month or three months caused reductions in peripheral blood and lymphoid organ T -cells. No other data are available on the effects of exposure to LFA3TIP. Carcinogenic effects data: No data available. Mutagenic Effects data: None observed in animal studies. LFA3TIP was negative in the bacterial mutagenicity assay, and non-clastogenic in in vitro human PBL cytogenetics assay. Reproductive/Teratogenic Effects data: No effects on reproductive tissues from male and female baboons were observed following repeat dose administration of LFA3TIP up to 20 mg/kg for 3 months.

Section 12. Ecological Information

No data available.

Section 13. Disposal Considerations

LFA3TIP is not a regulated hazardous material. It is water soluble and may be disposed of as aqueous waste in accordance with state and local regulatory requirements.

Section 14. Transport Information

DOT Proper Shipping Name: n/a Hazard Class: n/a ID #: n/a

Section 15. Regulatory Information

No data available.

Section 16. Other Information

MSDS Created: 1-Mar-95 Revised: 4-Mar-97 Prepared By: Susan B. Lee, CIH Manager, Environmental Health and Safety DISCLAIMER: The above mentioned data are based on Biogen's best present knowledge of this product. Biogen cannot guarantee completeness or accuracy of the information contained herein, and disclaims all liability for incompleteness or inaccuracy of the information and for any claims of damages arising from handling or use of this product.